17 Proteomics, Genomics & Microarrays Clinical-grade Recombinant Proteins for Cell Therapy
AMSBIO announces the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications. Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.
All StemFit Purotein® products are designed and manufactured under a strict animal-free protocol which minimises risk of virus contamination and ensures high lot-to-lot consistency. Manufactured using a streamlined (optionally GMP compliant) production and purification process results in recombinant proteins of the highest purity and quality while maintaining affordable prices. The StemFit Purotein® range includes recombinant proteins that play key roles in differentiation of ES and iPS cells into liver, pancreas, kidney, heart, blood, and immune cells. Beneficially, StemFit Purotein® products are supplied in a ‘ready-to-use’ frozen liquid form which eliminates the time-consuming process of reconstitution while ensuring consistent results.
Purotein® products are fully compatible with the StemFit® range of xeno-free, chemically defined media which is proven to effectively maintain induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) under feeder-free conditions during the reprogramming, expansion and differentiation phases of stem cell culture and growth medium.
More information online:
ilmt.co/PL/Ryav New Range of Cellulose Acetate Equipment
Cleaver Scientific is introducing a new range of equipment and reagents for Cellulose Acetate Clinical Electrophoresis. Designed by life scientists to enhance clinical testing of biological protein samples as well as the Qualitative Identification and Quantification of Haemoglobin, Serum Protein and Lipoprotein analysis.
Cleaver Scientific offers the complete system solution for research and Clinical Electrophoretic Cellulose Acetate Analysis with their Compact and High- Resolution systems.
The main equipment range includes an ideal Horizontal Unit tank for standard membrane and gel cellulose acetate techniques which can accommodate strips and gels of up to 24 x 20cm, mini Horizontal Unit, a power supply, a high-quality Densitometer software and scanner.
Included in the range are a plethora of Supported and Un-Supported strips, ready kits, reagents, applicators, samples template; offering the ability to perform complete tests. The variety of accessories provided can meet your testing needs and can also be compatible with your existing equipment.
All the range has been carefully manufactured and designed to high quality standards to address both research and clinical routine diagnostic testing.
For further information on the new range of Cellulose Acetate Equipment please visit the Cleaver Scientific webpage. More information online:
ilmt.co/PL/vPGD
58107pr@reply-direct.com ADVERTORIAL
The Importance of mRNA Vaccines, and how the Correct Lyo and Fill/Finish Equipment can Support your mRNA Ambitions
Currently within the vaccine and pharmaceutical production sectors, one of the main focusses has been on utilising single strand mRNA in vaccines to maximise on its advantageous properties during the development phase, such as its integral role in protein synthesis and its adaptability in both the number and type of antigenic determinants it encodes. This makes it an attractive tool compared to ‘conventional’ vaccinology development methods. However, it does come with some challenges, the biggest of which being the temperature that mRNA needs to be kept at, which is below -20ºC; you may remember that storage temperatures being one of the key issues facing the initial rollouts of the Astra Zeneca & Pfi zer vaccines against Covid-19.
When approaching vaccine development and production that incorporates the use of mRNA, a pragmatic and effi cient way to resolve these challenges is to use lyophilisation or freeze drying to create a stable product that has controllable storage and cold-chain transportation properties, whilst retaining the product viability. This allows the vaccine to be kept at higher temperatures for longer, increasing stability of the vaccine and reduce running costs of low-temperature storage. When looking at upscaling your production, investing in correct equipment can save time, money and increase productivity as well.
57867pr@reply-direct.com
This article from Biopharma Group explores the importance of how the selection of appropriate lyophilisation and fi ll/fi nish equipment in relation your vaccine development can lower batch rejection, increase production effi ciency, and reduce long-term costs. In addition, it explains how to scale-up your production from early- stage R&D with freeze dryers through to ensuring your manufacturing and packaging production capabilities enables adaptability to market demand.
More information online:
ilmt.co/PL/R2QO 58345pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
